Dr. Eric Lefebvre is Chief Medical Officer at Tobira Therapeutics, Inc. Tobira is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and HIV. The company's lead product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5 being evaluated for the treatment of non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC).
Since joining Tobira in January 2012, Dr. Lefebvre has led the strategy, design and conduct of Tobira’s development program of CVC for the treatment of NASH, including a large, multinational Phase 2b study (CENTAUR; NCT02217475) in 289 adults with NASH and liver fibrosis and securing Fast Track designation from the FDA for CVC in this setting. In addition, Dr. Lefebvre led the conduct of a Phase 2b study of CVC in HIV-infected patients and the initiation of a proof-of-concept study of CVC in PSC (PERSEUS; NCT02653625).
Before joining Tobira, Dr. Lefebvre was employed at Janssen Pharmaceuticals for nearly 10 years, focused on global clinical development and commercialization of novel treatments for HIV/AIDS and hepatitis C infection. He held first industry position at GSK Canada in 2001, supporting development and commercialization efforts of HIV/AIDS therapies and vaccines.
His career in the pharmaceutical industry was preceded by 15 years of clinical practice and research in infectious diseases, focusing on the prevention, diagnosis and treatment of HIV/AIDS, viral hepatitis and other sexually transmitted diseases. Dr. Lefebvre received his MD degree from University of Montreal in 1988.